[Pubmed] Efgartigimod non-responders after the first treatment cycle in generalized myasthenia gravis: a retrospective a
Posté : 24 nov. 2025 12:00
Front Neurol. 2025 Nov 6;16:1715486. doi: 10.3389/fneur.2025.1715486. eCollection 2025.
ABSTRACT
OBJECTIVE: This study aimed to identify predictors of suboptimal response to efgartigimod in patients with generalized myasthenia gravis (gMG).
METHODS: In this single-center retrospective study, 35 gMG patients treated with efgartigimod were categorized into responders (n = 25) and non-responders (n = 10). Responders were defined by a reduction of >2 points in MG-ADL or >3 points in QMG score after one cycle, whereas non-responders showed improvement below these thresholds and subsequently responded to eculizumab. Demographic, clinical, and serological features were compared using univariate and multivariate analyses.
RESULTS: Non-responders had higher baseline gross motor and respiratory sub-scores. Univariate analysis revealed that thymoma, non-thymoma tumors, thyroid disease, and other autoimmune diseases were more common in non-responders. Multivariate analysis indicated that combinations of these factors were associated with a high predicted probability of poor response (up to 97.9%).
INTERPRETATION: Comorbidities including thymoma, other tumors, thyroid disease, and additional autoimmune disorders may predict reduced response to efgartigimod in gMG patients. Systematic evaluation of these factors could help optimize treatment selection.
PMID:41281548 | PMC:PMC12631618 | DOI:10.3389/fneur.2025.1715486
Source: https://pubmed.ncbi.nlm.nih.gov/4128154 ... 22+67771e2